

# DALFAMPRIDINE MAY ENHANCE THE EFFECTS OF PHYSICAL THERAPY ON GAIT IN PEOPLE WITH MULTIPLE SCLEROSIS

Prue Plummer<sup>1</sup>, Whitney Huryta<sup>2</sup>, Jessica Reynolds<sup>3</sup>, Silva Markovic-Plese<sup>1</sup>, Barbara Giesser<sup>4</sup>

<sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>2</sup>Pivot Physical Therapy, Burlington, NC; <sup>3</sup>Allied Rehab, Wake Forest, NC; <sup>4</sup>University of California Los Angeles, Los Angeles, CA

## RATIONALE

- Dalfampridine extended-release (DER) is a drug that improves gait speed in some people with MS<sup>1</sup>
- The therapeutic benefit of DER occurs in only 38% of patients<sup>1</sup>
- Physical therapy (PT) can also improve gait speed in MS and may be a valuable adjunct to DER<sup>2,3</sup>

## OBJECTIVE

To estimate the effect size of combining DER with PT on gait speed in people with MS, and to compare the effects to PT without DER

## METHODS


### Participants

- 8 people with MS with self-reported walking difficulty
- n=4 starting DER (usual care), n=4 not taking DER (Table 1)

**DER Intervention:** 10 mg twice per day, as prescribed

### PT Intervention:

- One-on-one multicomponent exercise and gait training with a physical therapist, 2x/week for 6 weeks, 40 mins per session
- Functional strengthening, balance, gait (treadmill and overground), and dual task training



- Primary and secondary outcome measures were assessed at weeks 0, 3, 9, 12. Participants taking DER continued medication in the follow up period.



### Primary outcome measure:

- Timed 25 Foot Walk Test (T25FW): fastest safe speed

### Secondary outcome measures:

- Single task gait speed (self-selected speed)
- Dual task gait speed (walking with "clock task")
- MSWS-12: self-perceived walking ability
- ABC scale: balance self-efficacy

## GAIT SPEED OUTCOMES

Table 1. Participant characteristics

Group/subject	Age (years)	Gender	MS Type	MS duration (years)	Fear of falling	# falls last year
DER+PT 1	59	F	RRMS	6	Y	1
DER+PT 2	59	F	RRMS	12	N	7
DER+PT 3	42	F	RRMS	4.3	Y	2
DER+PT 4	38	F	RRMS	2	Y	12
<b>DER+PT total</b>	<b>49.5 (SD 11.1)</b>			<b>6.1 (SD 4.3)</b>		<b>5.5 (SD 5.1)</b>
PT 1	63	F	SPMS	15.5	N	1
PT 2	65	F	RRMS	5.8	N	1
PT 3	53	M	PPMS	0.5	N	3
PT 4	29	F	RRMS	5	Y	2
<b>PT total</b>	<b>52.5 (SD 16.5)</b>			<b>6.7 (SD 6.3)</b>		<b>1.8 (SD 1.0)</b>

## TIMED 25-FOOT WALK




Figure 1. T25FW changes in (A) seconds and (B) percent change from baseline. Bars = SEM

- All DER participants fell below the 20% improvement clinically important threshold after 3 weeks of DER (mean: 12.8%, range: 5.8-19.4%)
- Significantly greater improvement in T25FW from week 3-9 in DER group (p=.004)
  - DER+PT increase **20.7%** (95% CI: 3.8-37.6)
  - PT group by **6.8%** (95% CI: 3.4-10.3)
- Overall week 0-9 increase in T25FW was 30.5% for DER+PT, with all participants exceeding clinically important "responder" threshold of 20% improvement

## SELF-SELECTED SINGLE-TASK AND DUAL-TASK GAIT SPEED




Figure 2. Gait speed changes in (A) single-task self-selected speed and (B) dual-task self-selected speed. Bars = SEM

- Single-task gait speed: significant Group x Time interaction (p=.02,  $\eta_p^2=0.48$ )
  - DER+PT significant increase in gait speed week 3-9 (**0.15 m/s**, SD 0.09)
  - PT group no change
- Dual-task gait speed: main effect of Time (p=.005,  $\eta_p^2=0.59$ )
  - Significant increase in dual-task gait speed during PT phase (week 3-9, **0.10 m/s**)

## SECONDARY OUTCOMES




Figure 3. Changes in (A) ABC and (B) MSWS-12 scores

### Balance self-efficacy (ABC score)

- Both groups significantly improved in balance self-efficacy in week 3-9 (no change week 0-3)
- Significantly greater improvement in the DER+PT group (**21.6 points**) than the PT group (**7.0 points**) (p=.003)

### Self-perceived walking disability (MSWS-12)

- No change in self-rated disability in DER+PT group week on DER only (week 0-3), consistent with actual gait speed changes
- DER+PT group significantly improved week 3-9
- No change in PT group, but these participants had lower perceived walking disability, on average, at baseline

## SUMMARY

- PT may enhance the effects of DER on gait speed in people with MS who do not reach the responder threshold for a meaningful improvement on DER alone
- DER may enhance the effects of PT and exercise, since the benefits of PT were greater in those taking DER
- There was large variation between participants, so larger studies are needed to obtain more precise estimates of treatment effects

## References & Acknowledgements

- Goodman et al. *Int J MS Care* 2014;16:153-160
- Plummer *Int J MS Care* 2016;18:105-115
- Vaney et al. 2012. *Neurorehabil Neural Repair* 2012;26:212-221
- Goodman et al. *Neurology* 2008;71:1134-1141

The authors thank Gozde Iyigun and Jasmine Martin for conducting the evaluations, and Amy Thomas, Corinne Bohling, Alexis Williams, and Ellese Nickles for assistance providing PT interventions. We sincerely thank the staff at Steps For Recovery and the Campbell University Department of Physical Therapy for providing intervention facilities. This research was supported by the National MS Society (PP-1503-03495, Plummer).